A Phase I Study of Buparlisib (BKM120) and Ofatumumab or Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Trial Profile

A Phase I Study of Buparlisib (BKM120) and Ofatumumab or Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Buparlisib (Primary) ; Ibrutinib; Ofatumumab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Sep 2016 Planned End Date changed from 1 Jan 2023 to 1 Sep 2017.
    • 15 Sep 2016 Planned primary completion date changed from 1 Jan 2020 to 1 Sep 2017.
    • 15 Sep 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top